Abstract: Aspects of the present disclosure involve a system and a method for performing operations comprising: receiving, by a messaging application implemented on a client device, input that selects a sound option to add sound to one or more images; in response to receiving the input, presenting a sound editing user interface element that visually indicates a played portion of the sound and separately visually indicates an un-played portion of the sound; receiving an interaction with the sound editing user interface element to modify a start point of the sound; embedding a graphical element representing the sound in the one or more images; playing, by the messaging application, the sound associated with the graphical element starting from the start point together with displaying the one or more images.

Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant poly-peptide or variant disclosed herein to a subject in need thereof.

Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Abstract: A transport device cart having a frame assembly having one or more arms corresponding to and capable of engaging a removable bucket; one or more movement mechanisms; and a latching post. It also includes a latching assembly rotatably coupled to the frame assembly having a hooking latch capable of engaging and disengaging the latching post. A handle assembly is coupled to the latching assembly, wherein the handle assembly can be rotated back and used to push the removable bucket into a substantially inverted position.

Abstract: A transport device cart having a frame assembly having one or more arms corresponding to and capable of engaging a removable bucket; one or more movement mechanisms; and a latching post. It also includes a latching assembly rotatably coupled to the frame assembly having a hooking latch capable of engaging and disengaging the latching post. A handle assembly is coupled to the latching assembly, wherein the handle assembly can be rotated back and used to push the removable bucket into a substantially inverted position.

Abstract: A transport device having a removable bucket. The bucket includes one or more tracks on opposite sides. The transport device includes a frame assembly having one or more arms corresponding to and capable of engaging the tracks. It also includes one or more movement mechanisms such as wheels or tracks. A latching assembly is also included. The latching assembly is rotatably coupled to the frame assembly and is also coupled to a handle assembly.

Abstract: A transport device removable bucket. The bucket includes a first, second, third and fourth wall defining an enclosure. A first track is on an outside surface of the first wall and a second track is on an outside surface of the second wall. The first and second tracks correspond to one or more arms on a frame assembly. In one embodiment, the first and second tracks are affixed to the first and second walls respectively. In another embodiment, the tracks are integrated into the walls. The tracks can include vertical elements at which point they are attached to the walls. The tracks can be overhangs created by a narrowing of a bottom portion of the removable bucket. In one embodiment, the tracks are substantially v-shaped.

Abstract: A transport device cart having a frame assembly having one or more arms corresponding to and capable of engaging a removable bucket; one or more movement mechanisms; and a latching post. It also includes a latching assembly rotatably coupled to the frame assembly having a hooking latch capable of engaging and disengaging the latching post. A handle assembly is coupled to the latching assembly, wherein the handle assembly can be rotated back and used to push the removable bucket into a substantially inverted position.

Abstract: CPUs that generate PCIe auxiliary signals and changing clock signals nevertheless communicate with each other using PCIe owing to PCIe switch assemblies that are disposed in the communication paths to isolate and terminate the auxiliary signals from reaching other CPUs and to isolate changing clock signals, communicating with each other using a fixed clock derived from one of the changing clock signals. Also, the CPUs directly access the memories of CPUs to which they wish to write data so that data is directly written from one CPU memory to another without store-and-forward operations being needed in the network.